The landscape of stem cell medicine is changing, and it’s all about counting. There is growing awareness that the long-standing unmet need for specific counting of therapeutic tissue stem cells has been and continues to be a significant impediment to progress in stem cell therapy, gene and gene editing therapies (because targeting tissue stem cells is essential for durable one-time treatments), and drug development (because drug candidates that damage tissue stem cells fail miserably). In 2019, the FDA’s Standards Coordinating Body (SCB) listed determination of tissue stem cell-specific dose as a priority for standards development for stem cell clinical trials.

To evaluate your state of knowledge, take a few minutes to answer only 6 brief questions below.

AsymmetrexStem Cell Counting Study